生物制剂靶向治疗2型炎症的慢性阻塞性肺疾病的研究进展
Advances in Biologic Therapies Targeting Type 2 Inflammation in Chronic Obstructive Pulmonary Disease
DOI: 10.12677/acm.2026.1693167, PDF,   
作者: 肖焱月：吉首大学医学院，湖南 吉首；吉首大学第四临床学院，湖南 吉首；张在其*：吉首大学第四临床学院，湖南 吉首
关键词: 慢性阻塞性肺疾病；2型炎症；嗜酸性粒细胞；生物制剂；靶向治疗；Chronic Obstructive Pulmonary Disease； Type 2 Inflammation； Eosinophils； Biologics； Targeted Therapy
摘要: 慢性阻塞性肺疾病中约20%~40%的患者以嗜酸性粒细胞升高的2型炎症，这部分患者接受三联吸入维持治疗后仍出现反复急性加重和肺功能进行性下降。近年来，靶向IL-5/IL-5Rα、IL-4Rα、IL-33/ST2及TSLP等特定炎症通路的生物制剂为COPD患者提供了精准治疗的方向。本文旨在综述生物制剂靶向治疗2型炎症的慢性阻塞性肺疾病的研究进展，希望为临床医生实现慢性阻塞性肺疾病治疗的精准化与个体化。
Abstract: Approximately 20%~40% of patients with chronic obstructive pulmonary disease (COPD) exhibit type 2 inflammation characterized by elevated eosinophil counts. Despite receiving triple inhaled maintenance therapy, these patients often suffer from recurrent acute exacerbations and progressive lung function decline. In recent years, biologics targeting specific inflammatory pathways—such as IL-5/IL-5Rα, IL-4Rα, IL-33/ST2, and TSLP—have offered a direction for precision therapy in COPD. This article aims to review the research progress on biologic agents targeting type 2 inflammation in COPD, with the goal of assisting clinicians in achieving more precise and individualized management of the disease.
文章引用：肖焱月, 张在其. 生物制剂靶向治疗2型炎症的慢性阻塞性肺疾病的研究进展[J]. 临床医学进展, 2026, 16(9): 1313-1319. https://doi.org/10.12677/acm.2026.1693167

参考文献

[1] Global Initiative for Chronic Obstructive Lung Disease (2025) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2026 Report).
https://goldcopd.org/wp-content/uploads/2026/01/GOLD-REPORT-2026-v1.3-8Dec2025_WMV2.pdf
[2] Naghavi, M., Kyu, H.H., Aalipour, M.A., Aalruz, H., Ababneh, H.S., et al. (2025) Global Burden of 292 Causes of Death in 204 Countries and Territories and 660 Subnational Locations, 1990-2023: A Systematic Analysis for the Global Burden of Disease Study 2023. The Lancet, 406, 1811-1872.
https://doi.org/10.1016/s0140-6736(25)01917-8
[3] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 中国慢性阻塞性肺疾病基层诊疗与管理指南(2024年) [J]. 中华全科医师杂志, 2024, 23(6): 578-602.
[4] 廖艺璇, 郭岩斐. 《全球慢性阻塞性肺疾病诊断、管理及预防策略(2026版)》解读: 生物制剂治疗[J]. 国际呼吸杂志, 2026, 46(3): 196-201.
[5] Vanetti, M., Visca, D., Ardesi, F., Zappa, M., Pignatti, P. and Spanevello, A. (2025) Eosinophils in Chronic Obstructive Pulmonary Disease. Therapeutic Advances in Respiratory Disease, 19.
https://doi.org/10.1177/17534666251335800
[6] Rabe, K.F., Rennard, S., Martinez, F.J., Celli, B.R., Singh, D., Papi, A., et al. (2023) Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook. American Journal of Respiratory and Critical Care Medicine, 208, 395-405.
https://doi.org/10.1164/rccm.202303-0455ci
[7] Chen, Y., Yang, T., Zhang, J., Chen, X., Chen, X., Cheng, Z., et al. (2025) Type 2 Inflammation in Chronic Obstructive Pulmonary Disease: A Promising Treatable Trait and Practice Recommendations. Chinese Medical Journal Pulmonary and Critical Care Medicine, 3, 225-245.
https://doi.org/10.1016/j.pccm.2025.11.004
[8] Jia, N., Jin, M., Liu, Y., Su, N., Sun, Y., Tang, W., et al. (2025) The Management of Type 2 Inflammatory Respiratory Diseases: A Chinese Expert Consensus [2024]. Journal of Thoracic Disease, 17, 1807-1831.
https://doi.org/10.21037/jtd-2024-2092
[9] Sneha, H.R., Dhanush, Y., Rajaram, C., Nelson Kumar, S. and Siva Ganesh, V. (2026) Epithelial Alarmins TSLP, IL-33, and IL-25 in Asthma Pathogenesis: Mechanistic Roles and Therapeutic Implications. Molecular Biology Reports, 53, Article No. 828.
https://doi.org/10.1007/s11033-026-12005-4
[10] Bhatt, S.P., Rabe, K.F., Hanania, N.A., Vogelmeier, C.F., Cole, J., Bafadhel, M., et al. (2023) Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. New England Journal of Medicine, 389, 205-214.
https://doi.org/10.1056/nejmoa2303951
[11] Portacci, A., Pelaia, C., Bagnasco, D., Paoletti, G., Nolasco, S. and De Paulis, A. (2026) Lung Function Decline in Asthma: Mechanisms, Risk Factors, and Clinical Implications for Personalized Management. The Journal of Allergy and Clinical Immunology: In Practice, 14, 1295-1308.
https://doi.org/10.1016/j.jaip.2026.01.043
[12] Sahnoon, L., Bajbouj, K., Mahboub, B., Hamoudi, R. and Hamid, Q. (2025) Targeting IL-13 and IL-4 in Asthma: Therapeutic Implications on Airway Remodeling in Severe Asthma. Clinical Reviews in Allergy & Immunology, 68, Article No. 44.
https://doi.org/10.1007/s12016-025-09045-2
[13] Xie, C., Wei, Y., Su, C., et al. (2026) Mechanisms and Therapeutic Strategies of Asthma: From Bench to Bedside. Signal Transduction and Targeted Therapy, 11, Article No. 317.
https://doi.org/10.1038/s41392-026-02853-8
[14] Christenson, S.A., Hanania, N.A., Bhatt, S.P., Bafadhel, M., Rabe, K.F., Vogelmeier, C.F., et al. (2025) Type 2 Inflammation Biomarkers and Their Association with Response to Dupilumab in COPD (BOREAS): An Analysis of a Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Respiratory Medicine, 13, 687-697.
https://doi.org/10.1016/s2213-2600(25)00044-x
[15] 中华医学会呼吸病学分会肺功能学组. 呼出气一氧化氮检测流程及临床应用专家共识(2025版) [J]. 国际呼吸杂志, 2025, 45(5): 369-381.
[16] Kwok, W.C., Chau, C.H., Tam, T.C.C., Lam, F.M. and Ho, J.C.M. (2023) Variability of Blood Eosinophil Count at Stable-State in Predicting Exacerbation Risk of Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease, 18, 1145-1153.
https://doi.org/10.2147/copd.s401357
[17] Qi, Q., Peng, W., Yang, B., Liu, S., Pu, Y. and Zhou, Q. (2026) Biologics for Eosinophilic COPD: Current Applications and Future Prospects. Frontiers in Immunology, 17, Article 1722371.
https://doi.org/10.3389/fimmu.2026.1722371
[18] Sciurba, F.C., Criner, G.J., Christenson, S.A., Martinez, F.J., Papi, A., Roche, N., et al. (2025) Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. New England Journal of Medicine, 392, 1710-1720.
https://doi.org/10.1056/nejmoa2413181
[19] Fujino, N. and Sugiura, H. (2026) Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine. Respirology, 31, 561-577.
https://doi.org/10.1002/resp.70244
[20] Dransfield, M.T. and Stolz, D. (2025) Mepolizumab in COPD—If at First You Don’t Succeed. New England Journal of Medicine, 392, 1746-1748.
https://doi.org/10.1056/nejme2503292
[21] Agusti, A., Singh, D. and Faner, R. (2025) Treatment of Chronic Obstructive Pulmonary Disease: Current Pipeline and New Opportunities. Nature Reviews Drug Discovery, 25, 98-115.
https://doi.org/10.1038/s41573-025-01290-6
[22] Criner, G.J., Celli, B.R., Brightling, C.E., Agusti, A., Papi, A., Singh, D., et al. (2019) Benralizumab for the Prevention of COPD Exacerbations. New England Journal of Medicine, 381, 1023-1034.
https://doi.org/10.1056/nejmoa1905248
[23] Criner, G.J., Celli, B.R., Singh, D., Agusti, A., Papi, A., Jison, M., et al. (2020) Predicting Response to Benralizumab in Chronic Obstructive Pulmonary Disease: Analyses of GALATHEA and TERRANOVA Studies. The Lancet Respiratory Medicine, 8, 158-170.
https://doi.org/10.1016/s2213-2600(19)30338-8
[24] Pitre, T., Lupas, D., Mah, J., Stanbrook, M., Blazer, A., Zeraatkar, D., et al. (2025) Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. COPD: Journal of Chronic Obstructive Pulmonary Disease, 22, Article ID: 2449889.
https://doi.org/10.1080/15412555.2025.2449889
[25] Bhatt, S.P., Rabe, K.F., Hanania, N.A., Vogelmeier, C.F., Bafadhel, M., Christenson, S.A., et al. (2024) Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. New England Journal of Medicine, 390, 2274-2283.
https://doi.org/10.1056/nejmoa2401304
[26] Bhatt, S.P., Rabe, K.F., Hanania, N.A., Vogelmeier, C.F., Bafadhel, M., Christenson, S.A., et al. (2025) Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials. The Lancet Respiratory Medicine, 13, 234-243.
https://doi.org/10.1016/s2213-2600(24)00409-0
[27] Papi, A., Greening, N.J., Bhatt, S.P., Roche, N., Celli, B., Wedzicha, J.A., et al. (2026) Safety and Efficacy of Astegolimab for COPD with Frequent Exacerbations Regardless of Baseline Blood Eosinophil Counts (ALIENTO and ARNASA): Randomised, Double-Blind, Placebo-Controlled, Phase 2b and 3 Trials. The Lancet, 407, 2027-2039.
https://doi.org/10.1016/s0140-6736(26)00637-9
[28] Watz, H., Sciurba, F.C., Bonini, M., Yañez, A., Bourdin, A., Zheng, J., et al. (2026) Phase III LUNA Clinical Programme: Design of Four Randomised, Double-Blind, Placebo-Controlled Studies Assessing the Efficacy and Safety of Tozorakimab in Patients with Symptomatic COPD and a High Risk of Exacerbations. BMJ Open Respiratory Research, 13, e004145.
https://doi.org/10.1136/bmjresp-2026-004145
[29] Singh, D., Guller, P., Reid, F., Doffman, S., Seppälä, U., Psallidas, I., et al. (2025) A Phase 2a Trial of the IL-33 Monoclonal Antibody Tozorakimab in Patients with COPD: Frontier-4. European Respiratory Journal, 66, Article ID: 2402231.
https://doi.org/10.1183/13993003.02231-2024
[30] Rabe, K.F., Celli, B.R., Wechsler, M.E., Abdulai, R.M., Luo, X., Boomsma, M.M., et al. (2021) Safety and Efficacy of Itepekimab in Patients with Moderate-to-Severe COPD: A Genetic Association Study and Randomised, Double-Blind, Phase 2a Trial. The Lancet Respiratory Medicine, 9, 1288-1298.
https://doi.org/10.1016/s2213-2600(21)00167-3
[31] Singh, D., Brightling, C.E., Rabe, K.F., Han, M.K., Christenson, S.A., Drummond, M.B., et al. (2025) Efficacy and Safety of Tezepelumab versus Placebo in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COURSE): A Randomised, Placebo-Controlled, Phase 2a Trial. The Lancet Respiratory Medicine, 13, 47-58.
https://doi.org/10.1016/s2213-2600(24)00324-2
[32] Mappin-Kasirer, B. and Pavord, I.D. (2025) Biological Therapies in Chronic Obstructive Pulmonary Disease: New Directions in Personalised Respiratory Medicine. BioDrugs, 39, 827-839.
https://doi.org/10.1007/s40259-025-00744-y

为你推荐